USFDA Looks for Ways to Speed up Plant Inspections

The move has been triggered by the shortage of drugs — most of them supplied by Indian generic drug companies — that the US faces during the Covid-19 pandemic. The Indian Pharmaceutical Alliance has asked the FDA last month to find a solution for inspecting the manufacturing plants of its members.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Z6Kqsv
via IFTTT